Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

·       Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis (RMS)

·       Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomide

·       Fenebrutinib could become a first-in-class BTK inhibitor and the first and only high-efficacy oral for both RMS and primary progressive multiple sclerosis (PPMS) 

·       The totality of RMS and PPMS data for fenebrutinib will be submitted to regulatory authorities

South San Francisco, CA — April 21, 2026 —

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed that fenebrutinib, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, reduced the annualized relapse rate (ARR) by 51.1% (p<0.001) in FENhance 1 and 58.5% (p<0.0001) in FENhance 2 compared with teriflunomide in patients with relapsing multiple sclerosis (RMS) over 96 weeks. This equates to patients having approximately one relapse every 17 years, more than half the relapses seen with teriflunomide in the same period of time. The results were shared today as a late-breaking presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago.

“These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within the central nervous system and periphery to address disease mechanisms underlying both relapsing and progressive disease biology,” said Jiwon Oh, M.D., Ph.D., Medical Director of the Barlo Multiple Sclerosis Program at St. Michael’s Hospital, University of Toronto. “For the first time, a BTK inhibitor has demonstrated superiority in reducing relapses and formation of new brain lesions with comparable rates of liver enzyme elevations to a long-standing first-line medication in multiple Phase III RMS trials.”

“The fenebrutinib data across three pivotal studies strongly support its potential to benefit people with both RMS and PPMS,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “By more than doubling the time without relapses compared to teriflunomide, fenebrutinib may offer patients years of relapse-free living, thereby preserving both daily independence and long-term function.”

The relapse rate was consistently reduced across patient subgroups. The greatest reductions were observed in patients with more inflammatory disease characteristics including active brain lesions, younger age, more recent diagnosis and less disability, which highlights the potential of fenebrutinib as a high-efficacy, oral treatment option for these patient populations, if approved.

Secondary endpoints showed that fenebrutinib significantly reduced disease activity in the brain, as evidenced by MRI scans. Fenebrutinib reduced markers of active inflammation by 70.7% (p<0.0001) in FENhance 1 and 77.6% (p<0.0001) in FENhance 2 compared with teriflunomide, as measured by new T1 gadolinium-enhancing (T1-Gd+) lesions. Chronic disease burden was reduced by 76.0% (p<0.0001) in FENhance 1 and 82.5% (p<0.0001) in FENhance 2 with fenebrutinib compared with teriflunomide, as measured by new or enlarging T2 lesions.

Additional secondary endpoints showed positive trends toward reducing disability progression with fenebrutinib. A numerical reduction in the risk of 12-week composite confirmed disability progression (cCDP12) by 20% (hazard ratio [HR] 0.80; 95% confidence interval [CI]: 0.63-1.02) in FENhance 1 and 13% (HR 0.87; 95% CI: 0.69-1.11) in FENhance 2 was observed with fenebrutinib compared with teriflunomide. cCDP incorporates three measures of disability – total functional disability measured by confirmed disability progression (CDP) based on the Expanded Disability Status Scale (EDSS), walking speed measured by the timed 25-foot walk (T25FW) and upper limb function measured by the nine-hole peg test (9HPT). The greatest reductions were observed on overall disability and upper-limb disability. In a post-hoc analysis of a modified 12-week confirmed composite of the EDSS and the 9HPT, fenebrutinib reduced the risk of worsening by 26% (HR 0.74; 95% CI: 0.53-1.03) in FENhance 1 and 20% (HR 0.80; 95% CI: 0.57-1.12) in FENhance 2 compared with teriflunomide.

In both RMS studies, liver enzyme elevations above three times the upper limit of normal were comparable with teriflunomide (7.3% vs 5.7% in FENhance 1; 5.6% vs 5.6% in FENhance 2). In the FENhance 1 study, there was one Hy’s Law case in the fenebrutinib arm (which occurred before biweekly liver monitoring was implemented) and one in the teriflunomide arm. Both cases were asymptomatic and resolved after study drug discontinuation.

Rates of infections were also comparable between the fenebrutinib and teriflunomide arms. Serious adverse events (AEs) were reported in 8.6% of patients receiving fenebrutinib (vs 8.9% on teriflunomide) in FENhance 1 and 11.2% (vs 6.1%) in FENhance 2.

Overall, an imbalance with respect to reported fatalities across studies was observed. In FENhance 1 and 2, there was one death (0.1%) in the teriflunomide arm and seven deaths (0.9%) in the fenebrutinib arm during the reporting period. One additional death was observed after this period. Overall in the fenebrutinib arm, deaths occurred at different timepoints and were caused by various causes including infections (neuro cryptococcosis gattii and pneumonia), complications of type 1 diabetes, serious bleeding, suicide, injuries from accident and death of unknown cause.

Previously, the Phase III FENtrepid study in primary progressive multiple sclerosis (PPMS) showed fenebrutinib met its primary endpoint of non-inferiority compared with the current standard of care, Ocrevus®, in reducing disability progression in PPMS. The collective positive results across all three pivotal studies demonstrate that fenebrutinib consistently showed a profound benefit on relapsing and progressive disease biology. The totality of data from all three Phase III fenebrutinib studies will be submitted to regulatory authorities.

About the FENhance 1 and 2 studies 

FENhance 1 and 2 are two Phase III multicenter, randomized, double-blind, double-dummy, parallel-group studies to evaluate the efficacy and safety of investigational fenebrutinib compared with teriflunomide in a total of 1,497 adult patients with RMS. Eligible participants were randomized 1:1 to receive treatment with either oral fenebrutinib twice a day (and placebo matched to oral teriflunomide once a day) or oral teriflunomide once a day (and placebo matched to oral fenebrutinib twice a day) for at least 96 weeks.

The primary endpoint is annualized relapse rate (ARR). Secondary endpoints include total number of T1-gadolinium-enhancing MRI lesions, total number of new and/or enlarging T2-weighted MRI lesions, time to onset of 12-week composite confirmed disability progression (cCDP12) and 24-week cCDP (cCDP24).

About fenebrutinib  – Click here to continue reading